|Bid||0.0000 x 3200|
|Ask||1.2800 x 1100|
|Day's Range||1.2100 - 1.3800|
|52 Week Range||1.2100 - 15.0400|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 23, 2021 - Nov 24, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|Ex-Dividend Date||Apr 23, 2008|
|1y Target Est||6.50|
Subscribe to Yahoo Finance Plus to view Fair Value for ENVBLearn more
Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a patient-centric biotechnology company developing next-generation mental health and oncology treatments by leveraging psychedelic-derived molecules for the mind and synthetic cannabinoids for the body, today announced that Dr. Joseph Tucker, Chief Executive Officer of Enveric Biosciences, will participate in the H.C. Wainwright 2nd Annual Psychedelics Conference to be hosted virtually on Monday, December 6, 2021.
Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a patient-centric biotechnology company developing next-generation mental health and cancer support care therapies by leveraging psychedelic-derived molecules for the mind and synthetic cannabinoids for the body, today announced that EV102, the Company's cannabidiol (CBD) based product in development for topical prescription treatment of radiodermatitis, has demonstrated significant and meaningful reduction in dermatitis severity,
Key Takeaways: Trulieve, TerrAscend, and Verano Holdings amongst Top Cannabis Gainers for the Week. Awakn Findings from Phase II A/B KARE Study to Be Published In American Journal of Psychiatry; Awakn to Participate at the Wonderland: Miami Conference. FDA Authorizes IND for Sponsored Feasibility Study Using Kernel’s Flow Technology – Cybin Launches EMBARK Psychedelic Facilitator […] The post Cannabis Sector Weekly Roundup appeared first on Market Exclusive.